Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder.
Major depressive disorder (MDD) is blaimed to play a role in the onset of coronary artery disease (CAD). The aim of the present study was to investigate serum paraoxonase/arylesterase activities and oxidation of apolipoprotein B-containing lipoproteins in patients with MDD. Oxidation of lipoproteins plays an important role in atherogenesis and the enzyme paraoxonase, has been shown to prevent lipoprotein oxidation. Furthermore, low paraoxonase activity was suggested to predict CAD. Eighty-six patients who fully met the fourth Diagnostic and Statistical Manual of Mental Disorders criteria for MDD and 36 healthy control subjects were included in the study. Serum paraoxonase and arylesterase activities were determined spectrophotometrically. Malondialdehyde (MDA) levels of apolipoprotein B-containing lipoproteins were determined before (basal) and after incubation with copper-sulphate, that yielded basal- and Delta-MDA values, respectively. Serum paraoxonase/arylesterase activities were significantly reduced in the post-treatment group compared with the pre-treatment group. Basal-MDA (MDA) level was significantly higher in the MDD group compared with the control group. Delta-MDA level of the severe MDD group was significantly higher than that of the control group. There was a positive correlation between the oxidizability of apolipoprotein B-containing lipoproteins and the severity of the disease. Total cholesterol, HDL-cholesterol, LDL-cholesterol, apolipoprotein B levels were significantly higher and apolipoprotein AI levels were significantly lower in the MDD group compared with those of the control group. The findings of the present study suggest that: 1) antidepressant treatment might reduce serum paraoxonase activity/mass; 2) oxidation and oxidizability of apolipoprotein B-containing lipoproteins seem to be increased in MDD.
Sarandol
Asli
A
Department of Psychiatry, Uludag University Medical Faculty, 16059 Bursa, Turkey. asli@uludag.edu.tr
Sarandol
Emre
E
Eker
Salih Saygin
SS
Karaagac
Esra Ugurlu
EU
Hizli
Banu Zafer
BZ
Dirican
Melahat
M
Kirli
Selcuk
S
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001055:Apolipoproteins B / Q000097:blood*; D043303:Aryldialkylphosphatase / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism; D002265:Carboxylic Ester Hydrolases / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006710:Homocysteine / Q000097:blood; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D010084:Oxidation-Reduction; D010641:Phenotype; D011569:Psychiatric Status Rating Scales; D014280:Triglycerides / Q000097:blood
D000928:Antidepressive Agents; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008074:Lipoproteins; D014280:Triglycerides; D006710:Homocysteine; D008315:Malondialdehyde; D002097:C-Reactive Protein; D002784:Cholesterol; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043303:Aryldialkylphosphatase